PT - JOURNAL ARTICLE AU - Senkin, Sergey AU - Moody, Sarah AU - Díaz-Gay, Marcos AU - Abedi-Ardekani, Behnoush AU - Cattiaux, Thomas AU - Ferreiro-Iglesias, Aida AU - Wang, Jingwei AU - Fitzgerald, Stephen AU - Kazachkova, Mariya AU - Vangara, Raviteja AU - Le, Anh Phuong AU - Bergstrom, Erik N. AU - Khandekar, Azhar AU - Otlu, Burçak AU - Cheema, Saamin AU - Latimer, Calli AU - Thomas, Emily AU - Atkins, Joshua Ronald AU - Smith-Byrne, Karl AU - Penha, Ricardo Cortez Cardoso AU - Carreira, Christine AU - Chopard, Priscilia AU - Gaborieau, Valérie AU - Keski-Rahkonen, Pekka AU - Jones, David AU - Teague, Jon W. AU - Ferlicot, Sophie AU - Asgari, Mojgan AU - Sangkhathat, Surasak AU - Attawettayanon, Worapat AU - Świątkowska, Beata AU - Jarmalaite, Sonata AU - Sabaliauskaite, Rasa AU - Shibata, Tatsuhiro AU - Fukagawa, Akihiko AU - Mates, Dana AU - Jinga, Viorel AU - Rascu, Stefan AU - Mijuskovic, Mirjana AU - Savic, Slavisa AU - Milosavljevic, Sasa AU - Bartlett, John M.S. AU - Albert, Monique AU - Phouthavongsy, Larry AU - Ashton-Prolla, Patricia AU - Botton, Mariana R. AU - Neto, Brasil Silva AU - Bezerra, Stephania Martins AU - Curado, Maria Paula AU - de Cássio Zequi, Stênio AU - Reis, Rui Manuel AU - Faria, Eliney AU - Menezes, Nei Soares AU - Ferrari, Renata Spagnoli AU - Banks, Rosamonde E. AU - Vasudev, Naveen S. AU - Zaridze, David AU - Mukeriya, Anush AU - Shangina, Oxana AU - Matveev, Vsevolod AU - Foretova, Lenka AU - Navratilova, Marie AU - Holcatova, Ivana AU - Hornakova, Anna AU - Janout, Vladimir AU - Purdue, Mark AU - Rothman, Nathaniel AU - Chanock, Stephen J. AU - Ueland, Per Magne AU - Johansson, Mattias AU - McKay, James AU - Scelo, Ghislaine AU - Chanudet, Estelle AU - Humphreys, Laura AU - de Carvalho, Ana Carolina AU - Perdomo, Sandra AU - Alexandrov, Ludmil B. AU - Stratton, Michael R. AU - Brennan, Paul TI - Geographic variation of mutagenic exposures in kidney cancer genomes AID - 10.1101/2023.06.20.23291538 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.20.23291538 4099 - http://medrxiv.org/content/early/2023/10/26/2023.06.20.23291538.short 4100 - http://medrxiv.org/content/early/2023/10/26/2023.06.20.23291538.full AB - International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), for which obesity, hypertension, and tobacco smoking are risk factors but do not explain its geographical variation in incidence2. Some carcinogens generate somatic mutations and a complementary strategy for detecting past exposures is to sequence the genomes of cancers from populations with different incidence rates and infer underlying causes from differences in patterns of somatic mutations. Here, we sequenced 962 ccRCC from 11 countries of varying incidence. Somatic mutation profiles differed between countries. In Romania, Serbia and Thailand, mutational signatures likely caused by extracts of Aristolochia plants were present in most cases and rare elsewhere. In Japan, a mutational signature of unknown cause was found in >70% cases and <2% elsewhere. A further mutational signature of unknown cause was ubiquitous but exhibited higher mutation loads in countries with higher kidney cancer incidence rates (p-value <6 × 10−18). Known signatures of tobacco smoking correlated with tobacco consumption, but no signature was associated with obesity or hypertension suggesting non-mutagenic mechanisms of action underlying these risk factors. The results indicate the existence of multiple, geographically variable, mutagenic exposures potentially affecting 10s of millions of people and illustrate the opportunities for new insights into cancer causation through large-scale global cancer genomics.Competing Interest StatementLBA is a compensated consultant and has equity interest in io9, LLC and Genome Insight. His spouse is an employee of Biotheranostics, Inc. LBA is also an inventor of a US Patent 10,776,718 for source identification by non-negative matrix factorization. ENB and LBA declare U.S. provisional applications with serial numbers: 63/289,601; 63/269,033; and 63/483,237. LBA also declares U.S. provisional applications with serial numbers: 63/366,392; 63/367,846; 63/412,835; and 63/492,348. VM received honoraria from Ipsen, Bayer, AstraZeneca, Janssen, Astellas Pharm and MSD, and provided expert testimony to BMS, Bayer, MSD and Janssen. No other authors declare any competing interests.Funding StatementThis work was delivered as part of the Mutographs team supported by the Cancer Grand Challenges partnership funded by Cancer Research UK (C98/A24032). This work was supported by the Wellcome Trust grants 206194 and 220540/Z/20/A. The work was also partly funded by Barretos Cancer Hospital, the Public Ministry of Labor of Campinas (Research, Prevention, and Education of Occupational Cancer, 2015 to R.M.R.), and by Hospital de Clinicas de Porto Alegre (180330 to P.A.-P., M.B., B.S.N.). The work was also partly supported by the Practical Research Project for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) (JP20ck0106547h0001 to T.S.), and by the National Cancer Center Japan Research and Development Fund (2020-A-7 to A.F.). The work was also partly funded by the 1st and 2nd Faculties of Medicine, Charles University, Prague (CAGEKID to I.H.; Occupation, Environment and Kidney Cancer in Central and Eastern Europe to A.H.). The work was also partly supported by the Ministry of Health of the Czech Republic (MH CZ - DRO (MMCI, 00209805) to L.F. and M.N.). Measurement of PFAS compounds was funded by Division of Cancer Epidemiology and Genetics of the National Cancer Institute (USA). Measurement of cystatin C was funded by Cancer Research UK (C18281/A29019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals were first obtained from each Local Research Ethics Committee and Federal Ethics Committee when applicable, as well as from the IARC Ethics Committee (IRB number: IEC Project 17-10)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWhole genome sequencing data and patient metadata are deposited in the European Genome-phenome Archive (EGA) associated with study EGAS00001003542. Aligned BAM files for all ccRCC cases included in the final analysis were deposited in dataset EGAD00001012102, variant calling files in dataset EGAD00001012222 and patient metadata in dataset EGAD00001012223. The metabolomics data are available upon request. All other data are provided in the accompanying Supplementary Tables. https://ega-archive.org/studies/EGAS00001003542 https://ega-archive.org/datasets/EGAD00001012102 https://ega-archive.org/datasets/EGAD00001012222 https://ega-archive.org/datasets/EGAD00001012223